Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Millan, Mark J.
Dekeyne, Anne
Gobert, Alain
Brocco, Mauricette
Mannoury la Cour, Clotilde
Ortuno, Jean-Claude
Watson, David
and
Fone, Kevin C.F.
2020.
Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs.
Neuropharmacology,
Vol. 177,
Issue. ,
p.
108099.
Sharp, Trevor
and
Barnes, Nicholas M.
2020.
Central 5-HT receptors and their function; present and future.
Neuropharmacology,
Vol. 177,
Issue. ,
p.
108155.
2021.
The Maudsley Prescribing Guidelines in Psychiatry.
p.
601.
Kucwaj-Brysz, Katarzyna
Baltrukevich, Hanna
Czarnota, Kinga
and
Handzlik, Jadwiga
2021.
Chemical update on the potential for serotonin 5-HT6 and 5-HT7 receptor agents in the treatment of Alzheimer’s disease.
Bioorganic & Medicinal Chemistry Letters,
Vol. 49,
Issue. ,
p.
128275.
Li, Xiaojiao
Gao, Lei
Liu, Jingrui
Zhang, Hong
Chen, Hong
Yang, Lizi
Wu, Min
Li, Cuiyun
Zhu, Xiaoxue
Ding, Yanhua
and
Sun, Li
2021.
Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, HEC30654, in Healthy Chinese Subjects.
Frontiers in Pharmacology,
Vol. 12,
Issue. ,
Collier, Jack J
Suomi, Fumi
Oláhová, Monika
McWilliams, Thomas G
and
Taylor, Robert W
2021.
Emerging roles of ATG7 in human health and disease.
EMBO Molecular Medicine,
Vol. 13,
Issue. 12,
Kucwaj-Brysz, Katarzyna
Ali, Wesam
Kurczab, Rafał
Sudoł-Tałaj, Sylwia
Wilczyńska-Zawal, Natalia
Jastrzębska-Więsek, Magdalena
Satała, Grzegorz
Mordyl, Barbara
Żesławska, Ewa
Agnieszka-Olejarz-Maciej
Czarnota, Kinga
Latacz, Gniewomir
Partyka, Anna
Wesołowska, Anna
Nitek, Wojciech
and
Handzlik, Jadwiga
2022.
An exit beyond the pharmacophore model for 5-HT6R agents - a new strategy to gain dual 5-HT6/5-HT2A action for triazine derivatives with procognitive potential.
Bioorganic Chemistry,
Vol. 121,
Issue. ,
p.
105695.
Fan, Fangcheng
Liu, Hua
Shi, Xiaojie
Ai, Yangwen
Liu, Qingshan
and
Cheng, Yong
2022.
The Efficacy and Safety of Alzheimer’s Disease Therapies: An Updated Umbrella Review.
Journal of Alzheimer's Disease,
Vol. 85,
Issue. 3,
p.
1195.
Czarnota-Łydka, Kinga
Kucwaj-Brysz, Katarzyna
Pyka, Patryk
Haberek, Wawrzyniec
Podlewska, Sabina
and
Handzlik, Jadwiga
2022.
Multitargeting the Action of 5-HT6 Serotonin Receptor Ligands by Additional Modulation of Kinases in the Search for a New Therapy for Alzheimer’s Disease: Can It Work from a Molecular Point of View?.
International Journal of Molecular Sciences,
Vol. 23,
Issue. 15,
p.
8768.
Xu Lou, Inmaculada
Chen, Jiayue
Ali, Kamran
Shaikh, Abdul Lateef
and
Chen, Qilan
2023.
Mapping new pharmacological interventions for cognitive function in Alzheimer’s disease: a systematic review of randomized clinical trials.
Frontiers in Pharmacology,
Vol. 14,
Issue. ,
Abdallah, Abdallah E.
2024.
Review on anti-alzheimer drug development: approaches, challenges and perspectives.
RSC Advances,
Vol. 14,
Issue. 16,
p.
11057.
Dhapola, Rishika
Kumari, Sneha
Sharma, Prajjwal
Vellingiri, Balachandar
and
HariKrishnaReddy, Dibbanti
2025.
Advancements in autophagy perturbations in Alzheimer’s disease: Molecular aspects and therapeutics.
Brain Research,
Vol. 1851,
Issue. ,
p.
149494.
Kastrati, Lum
Farina, Sara
Valz Gris, Angelica
Raeisi-Dehkordi, Hamidreza
Llanaj, Erand
Quezada-Pinedo, Hugo G
Bally, Lia
Muka, Taulant
and
Ioannidis, John P A
2025.
Evaluation of reported claims of sex-based differences in treatment effects across meta-analyses: a meta-research study.
BMJ Evidence-Based Medicine,
p.
bmjebm-2024-113359.
2025.
The Maudsley Prescribing Guidelines in Psychiatry.
p.
627.